Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Flaherty on the COLUMBUS Trial Updates in BRAF-Mutant Melanoma

July 24th 2019

Keith T. Flaherty, MD, discusses an update on overall survival in COLUMBUS, a randomized phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

ctDNA Monitoring Carries Clinical Validity in Advanced BRAF-Mutant Melanoma

July 23rd 2019

David Polsky, MD, PhD, discusses findings from an analysis in patients with BRAF-mutant, unresectable, metastatic melanoma, as well as the next steps for validating these findings and potentially using circulating tumor DNA to help inform treatment decisions.

Long Shares Insight on Pivotal Data in BRAF-Mutant Melanoma

July 10th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the activity of the combination of dabrafenib and trametinib alone as well as in combination with spartalizumab in patients with advanced BRAF V600E-mutant melanoma.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

July 9th 2019

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

FDA Approval Sought for Extended Pembrolizumab Dosing Schedule for Select Indications

July 9th 2019

The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.

Dr. Khushalani on Reasoning for the CA045-001 Trial

July 9th 2019

Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Dr. Sullivan on Practice-Changing COMBI-d and COMBI-v Trials

July 5th 2019

Ryan J. Sullivan, MD, discusses the results of the COMBI-d and COMBI-v studies that led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Polsky on Using ctDNA as a Biomarker for Melanoma

July 2nd 2019

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

Cemiplimab Approved in Europe for Cutaneous Squamous Cell Carcinoma

July 1st 2019

The European Commission approved cemiplimab (Libtayo) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

Adding PD-1 Inhibitor to Dabrafenib/Trametinib May Improve Outcomes in BRAF+ Melanoma

June 28th 2019

Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.

Atezolizumab/Cobimetinib Combo Misses PFS Endpoint in BRAF V600 Wild-Type Melanoma

June 21st 2019

The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial.

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

June 4th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Dr. Johnson on Applications of Immunotherapy in Melanoma

May 30th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses applications of immunotherapy in melanoma.

Immunotherapy Lessons Learned in Melanoma May Turn Tide in Other Tumors

May 22nd 2019

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Dr. Daud Discusses the Immunogenicity of Melanoma

May 17th 2019

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

May 17th 2019

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Dr. Sullivan on Immunotherapy Approaches in Melanoma

April 29th 2019

Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses treatment approaches with immunotherapy for patients with melanoma.

Cemiplimab Nears EU Approval for CSCC

April 29th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals, the manufacturer of the PD-1 inhibitor.

Dr. Sullivan on Findings From the ENCORE 601 Trial in Melanoma

April 10th 2019

Ryan J. Sullivan, MD, instructor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital (MGH), MGH Cancer Center, discusses findings from the ENCORE 601 trial in melanoma.

Dr. Johnson on Promise of Combination Therapy in Melanoma

April 5th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.

NEXT PAGE
PREVIOUS PAGE